Southeast Asset Advisors’s Maravai LifeSciences MRVI Stock Holding History

Southeast Asset Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-95,181	Closed	-$2.43M	–	137
2022 Q3	$2.43M	Sell	95,181 -13,514	-12%	-$339K	0.41%	37
2022 Q2	$3.09M	Buy	108,695 +1,269	+1%	+$40.2K	0.49%	31
2022 Q1	$3.79M	Buy	107,426 +2,231	+2%	+$74.8K	0.5%	33
2021 Q4	$4.41M	Buy	105,195 +41,706	+66%	+$1.69M	0.6%	30
2021 Q3	$3.12M	Buy	63,489 +33,458	+111%	+$1.63M	0.51%	43
2021 Q2	$1.25M	Buy	30,031 +10,626	+55%	+$412K	0.21%	69
2021 Q1	$692K	Buy	+19,405	New	+$643K	0.12%	82

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Southeast Asset Advisors's MRVI Position: Q4 2022 in Review

Southeast Asset Advisors sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 95,181 shares — an estimated $2.43M sold.

Southeast Asset Advisors first reported a position in MRVI in Q1 2021 and held it in 7 quarters. The position peaked at $4.41M in Q4 2021. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

Southeast Asset Advisors reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
Southeast Asset Advisors sold 95,181 Maravai LifeSciences shares in Q4 2022, an estimated $2.43M.
Southeast Asset Advisors first reported a position in Maravai LifeSciences in Q1 2021 and held it in 7 quarters.
Southeast Asset Advisors's Maravai LifeSciences position peaked at $4.41M in Q4 2021.
212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Southeast Asset Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.